Tamsulosin: Effect on quality of life in 2740 patients with lower urinary tract symptoms managed in real life practice in Spain

Archivos Espanoles de Urologia

Volumn 55, Issue 1, 2002, Pages 97-105

  Batista, J Emilio ^a   Palacio, Andrés ^b   Torrubia, Rafael ^e   Hernández, Carlos ^c   Vicente, José ^e   Resel, Luis ^d  

^a FUNDACIÓ PUIGVERT   (Spain)

^b HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^e Fundació Puigvert ^*

Author keywords

BPH, LUTS; Quality of Life; Real Life Practice; Spain; Tamsulosin

Indexed keywords

TAMSULOSIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE SEVERITY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; PROSTATE HYPERTROPHY; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SPAIN; TREATMENT OUTCOME; URINARY TRACT OBSTRUCTION; WELLBEING;

ACTIVITIES OF DAILY LIVING; ADRENERGIC ALPHA-ANTAGONISTS; AGED; COMORBIDITY; DIZZINESS; GASTROINTESTINAL DISEASES; HUMANS; HYPOTENSION; IMPOTENCE; MALE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT DROPOUTS; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; QUESTIONNAIRES; RECEPTORS, ADRENERGIC, ALPHA-1; SULFONAMIDES; TREATMENT OUTCOME;

EID: 0036198240     PISSN: 00040614     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. GARRAWAY, W.M.; COLLINS, G.N.; LEE, R.J.: "High prevalence of benign prostatic hypertrophy in the community." Lancet, 338: 469, 1991.
2. GIRMAN, C.J. et al.: "Health-related quality of life associated with lower urinary tract symptoms in four countries." Urology, 51: 428, 1998.
3. DEPARTMENT OF VETERANS AFFAIRS: "A comparison of quality of life with patient reported symptoms and objective findings in men with benign prostatic hyperplasia." J. Urol., 150: 1696, 1993.
4. CALAIS DA SILVA, F. et al.: "Relative importance of sexuality and quality of life in patients with prostatic symptoms. Results of an international study." Eur. Urol., 31: 272, 1997.
5. MACDONAGH, R.; PEAREY, R.: "Quality-of-life aspects in urology - benign prostatic hyperplasia." World J. Urol., 17: 199, 1999.
6. HOLTGREWE, H.L. et al.: "The economics of the management of lower urinary tract symptoms and benign prostatic hyperplasia." In: Denis L et al. (eds). Proceedings of the 4th International Consultation on BPH. Plymbridge Distributors Ltd: Plymouth, 1998, pp 63-81.
7. DENIS, L. et al.: "Recommendations of the International Scientific Committee: the evaluation and treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction." In: Denis L et al. (eds). Proceedings of the 4th International Consultation on BPH. Plymbridge Distributors Ltd: Plymouth, 1998, pp 669-684.
8. DEBRUYNE, F.M.J. et al.: "Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia." Eur. Urol., 34: 169, 1998.
9. KIRBY, R. et al.: "Results of the PREDICT (Prospective European Doxazosin and Combination Therapy) trial." J. Urol., 161(suppl): 266 (abs. 1027), 1999.
10. LEPOR, H. et al.: "The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response." J. Urol., 160: 1358, 1998.
11. ABBOU, C.C. et al.: "Alfuzosin, an uroselective alpha 1 blocker versus Pygeum africanum, a plant extract: a randomized controlled trial in patients with symptomatic benign prostatic hypertrophy (BPH)." Eur. Urol., 30 (suppl. 2): 77(abs. 241), 1996.
12. GRASSO, M. et al.: "Comparative effects of alfuzosin versus Serenoa repens in the treatment of symptomatic benign prostatic hyperplasia." Arch. Esp. Urol., 48: 97, 1995.
13. 1-adrenoceptorantagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction." Eur. Urol., 36: 1, 1999.
14. MICHEL, M.C.; BRESSEL, H-U.; MEHLBURGER, L. et al.: "Tamsulosin: real life clinical experience in 19,365 patients." Eur. Urol., 34 (suppl. 2): 37, 1998.
15. LUKACS, B.; MC CARTHY, C.; LEPLEGE, A. et al.: "Construction et validation d'une échelle de qualité de vie liée à l'état de santé, spécifique de l'hypertrophie bénigne de la prostate et comportant une échelle d'évaluation de la sexualité." Prog. Urol., 4: 688, 1994.
16. BATISTA-MIRANDA, J.L. et al.: "Cuestionario IPSS en pacientes y controles. Validación psicométrica." Actas Urol. Esp., 19: 93, 1995.
17. EPSTEIN, R.S. et al.: "Validation of a new quality of life questionnaire for benign prostatic hyperplasia." J. Clin. Epidemiol., 45: 1431, 1992.
18. VEIT, C.T. et al.: "The structure of psychological distress and well-being in general populations." J. Consult. Clin. Psych., 51: 730, 1983.
19. MACDONAGH: "Quality of life and its assessment in urology." Br. J. Urol., 78: 485, 1996.
20. MICHEL, M.C.; MEHLBURGER, L.; BRESSEL, H-U. et al.: "Comparison of tamsulosin efficacy in subgroups of patients with lower urinary tract symptoms." Prostate Cancer and Prostatic Diseases, 1: 332, 1998.
21. LA-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicenter studies in patients with benign prostatic obstruction (symptomatic BPH)." Eur. Urol., 29: 155, 1996.
22. BUZELIN, J.M. et al.: "Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia)." Br. J. Urol., 80: 597, 1997.
23. BARRY, M.J. et al.: "Measuring disease-specific health status in men with benign prostatic hyperplasia." Medical Care, 33: AS145, 1995.
24. LEPOR, H., for the Tamsulosin Investigator Group.: "Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia." Urology, 51: 892, 1998.
25. GUTHRIE, R.M.; SIEGEL, R.L.: "A multicenter, community-based study of doxazosin in the treatment of concomitant hypertension and symptomatic benign prostatic hyperplasia: the Hypertension and BPH Intervention Trial (HABIT)." Clin. Ther., 21: 1732, 1999
26. SANCHEZ-CHAPADO M. et al.: "Safety and efficacy of sustained-release alfuzosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia in 3095 Spanish patients evaluated during general practice." Eur. Urol., 37: 421, 2000.